Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 2,96 € (+228,89%). Mediana wynosi 2,96 € (+228,89%).
| Kupuj |
6 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Product recall weighs on Biote Q1: profit and revenue below expectations
Biote reports Q1 2026 EPS of $0.06 (expectation $0.10) and revenue of $44.9m (expectation $46.01m), mainly impacted by a voluntary recall of bioidentical hormone pellets. Revenue fell 8.3% year over year, treatment revenues declined 13.2%, while supplements rose 19.1% thanks to e‑commerce. The stock fell 5.43% in after‑hours trading. Despite the disruption, management reaffirms the full‑year guidance of >$190m in revenue and >$38m in adjusted EBITDA and expects a recovery in the second half of the year. » Więcej na de.investing.com
Biote misses Q1 forecasts: EPS and revenue fall short of expectations
Biote reported Q1 2026 earnings of $0.06 per share versus $0.10 expected and revenue of $44.9 million versus $46.01 million expected. Revenue fell 8.3% year‑on‑year, weighed down by a voluntary recall of bioidentical hormone pellets, while the supplements segment grew 19.1%. Management maintains its full‑year revenue guidance of over $190 million and expects treatment revenues to recover in the second half of the year. After the release, the stock fell 0.45% to $2.21. » Więcej na de.investing.com
Biote Corp misses Q4 2025 earnings forecast and reports revenue decline
Biote Corp reported Q4 2025 EPS of $0.06, missing the $0.09 estimate; revenue was $46.4 million, slightly below the expected $47.12 million. The supplement business grew 16% thanks to e‑commerce, but could not offset declines in treatment revenue and higher clinic churn. Gross margin fell due to inventory charges following a recall; the company expects treatment revenue headwinds through the first half of 2026 and growth in the supplement segment later in the year. » Więcej na de.investing.com
Biote Corp. subsidiary Asteria Health recalls hormone pellets over metal particle risk
Biote Corp. said its subsidiary F.H. Investments, operating as Asteria Health, has initiated a voluntary recall of certain batches of compounded bioidentical hormone pellets shipped between May 20, 2025 and January 19, 2026. The recall is due to potential contamination with metal particles and is being conducted with knowledge of the FDA. Biote expects a one‑time charge of about $1.3 million in the fourth quarter for write‑down of affected inventory and estimates additional recall costs for 2026 of roughly $1 million. The company does not expect significant further impact on supply to partner clinics and will disclose details of the financial effects with its Q4 results. » Więcej na de.investing.com
biote posts Q3 EPS 371% above forecasts; analysts trim 2026 EPS and price target
biote reported Q3 revenue of US$48m in line with expectations and statutory EPS of US$0.22, 371% above forecasts. After the results analysts left 2026 revenue estimates roughly unchanged at US$198.4m but cut consensus EPS to US$0.32 from US$0.34. The average price target fell 5.6% to US$4.61, and analysts now expect biote’s revenue growth to slow materially below industry peers. » Więcej na finance.yahoo.com
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 38,26 mln | 6,38% |
| Zysk brutto | 25,89 mln | 11,71% |
| Zysk netto | 359,32 tys. | 94,85% |
| EBITDA | 3,98 mln | 61,49% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 39,79 mln € |
Liczba akcji | 44,11 mln |
Maksimum/minimum z 52 tygodni | 2,64 € - 0,87 € |
| Dywidendy | Nie |
Beta | 1,74 |
C/Z (PE Ratio) | -12,84 |
PEG (PEG Ratio) | 0,12 |
C/WK (PB Ratio) | -0,41 |
C/S (PS Ratio) | 0,24 |
Profil spółki
biote Corp. prowadzi działalność w obszarze wspierania praktyk medycznych w ramach optymalizacji hormonalnej. Firma oferuje platformę dla lekarzy certyfikowanych przez biote, umożliwiającą korygowanie zaburzeń poziomu hormonów, witamin i minerałów u pacjentów, a także przepisywanie bioidentycznych terapii hormonalnych oraz zalecanie suplementów diety. Firma sprzedaje również suplementy diety marki Biote oraz sterylne zestawy do wszczepiania granulek dla mężczyzn i kobiet. Spółka została założona w 2011 roku i ma siedzibę w Irvine w Teksasie.
| Nazwa | Biote Corp |
| CEO | Robert C. Peterson |
| Siedziba | Irving,
tx Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Ochrona zdrowia: świadczeniodawcy i usługi |
| Debiut giełdowy | 28.04.2021 |
| Pracownicy | 223 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
Pnk | BTMD |